Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golden Gate Study of blinatumomab alternating with low-intensity chemotherapy versus standard of care in older adults with newly diagnosed Philadelphia-negative B-cell precursor acute lymphoblastic leukemia
2020-004498-29Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Amgen. Primary endpoint: Safety Run-in. Started Nov 2021; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2020-004498-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004498-29.